Aapproval of ILUVIEN(R) for the Trean
Alimera Sciences Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN(R) for the Treatment of Chronic Diabetic Macular Edema
6:30a ET February 28, 2012 (GlobeNewswire)
-- ILUVIEN(R) expected to be the first sustained release pharmaceutical in
the European Union to treat diabetic macular edema (DME)
-- ILUVIEN expected to be indicated for chronic DME considered
insufficiently responsive to available therapies